An appetite suppressant medication used in the management of obesity. Sibutramine (including all generic and brand [meridia] products) was withdrawn from the U.S. market in 2010 because of its association with increased cardiovascular events and strokes.
A medication with a central appetite-suppressing mechanism, utilized to address obesity in individuals who haven’t achieved success with alternative weight loss approaches like diet modification and physical activity. Typical adverse effects encompass constipation, dry mouth, and high blood pressure. Those using this medication should maintain regular check-ups, during which their blood pressure and pulse will be monitored.